The evolution of sanitized environments is an essential topic in the context of clean space engineering, especially in the pharmaceutical market. The recent review of Good Manufacturing Practices (GMP) by the European Commission and PIC/S reflects the changes needed to meet regulatory demands and technological advances. This article addresses this evolution and the innovations implemented, with emphasis on the construction of clean rooms where pharmaceutical equipment is installed.
You will find
History and Context of Clean Rooms
Since the first historical records, medical and pharmaceutical practices have undergone numerous transformations. In the 20th century, the “Golden Age of Discoveries” brought significant advances in drug manufacturing, culminating in the need for stricter regulations to ensure the quality and safety of pharmaceutical products.
The FDA began a new paradigm in pharmaceutical production in 1963 in the USA, introducing Good Manufacturing Practices (GMP) to ensure patient safety and drug integrity. In Brazil, ANVISA adopted these practices through Ordinance No. 16 in 1995, later evolving into RDC 301/2019, aligned with the PIC/S.
Review of GMP Guidelines
In August 2022, the European Commission launched a significant review of the EU GMP guidelines, with a one-year period for implementation. This review emphasizes the application of the principles of Quality Risk Management (QRM) and the Pharmaceutical Quality System (ICH Q9 and Q10). The new guidelines provide detailed guidance for the design and control of facilities, equipment and procedures, with the aim of minimizing microbial, particulate and endotoxin/pyrogen contamination.
Innovations and Updated Guidelines
The structure of the guidelines has been reorganized into specific topics, allowing for a more understandable assessment of requirements. Below are some of the main innovations:
1. Quality System
The evolution of clean rooms is crucial in the engineering of these areas, especially in the pharmaceutical sector. The recent update of Good Manufacturing Practices (GMP) by the European Commission and PIC/S highlights the required changes.
2. Facilities
The guidelines detail the use of barrier technologies, such as Restricted Access Barrier Systems (RABS), to separate Grade A environments from other areas. Clean area qualification now includes particle measurement and the implementation of a Contamination Control Strategy (CCS). This is a crucial point for the construction of clean roomsThis requires detailed planning and the use of materials and construction techniques that guarantee the integrity and sterility of the environment.
3. Equipment and Utilities
Maintaining equipment outside of clean areas is encouraged to reduce the risk of contamination. Utilities, such as water and steam systems, must be assessed through a risk analysis and continuously monitored. The construction of cleanrooms must consider the installation to ensure their optimal and safe operation.
4. Personal
The qualification and continuous training of personnel are crucial. The guidelines detail the need for knowledge in microbiology, aseptic techniques, and contamination control, reinforcing the importance of dedicated training and personal protective equipment (PPE) areas within the facilities. clean rooms.
5. Production and Specific Technologies
The guidelines cover sterilization processes in detail, emphasizing the need for rigorous validation and continuous monitoring. Automation and the use of RABS systems are recommended to minimize human interventions and reduce the risk of contamination. In the construction of clean rooms, this implies the need to integrate these technologies from the design phase.
6. Environmental and Process Monitoring
Environmental monitoring has advanced, defining new standards for particulate pollution and requiring the precise identification of microorganisms in critical areas. The simulation of aseptic processes must guarantee "zero growth," with no contaminated vials. This requires an environment of... clean room built with advanced monitoring systems and strategically located sampling points.
Conclusion
The revision of the EU GMP guidelines represents a significant advance in the regulation of the manufacture of sterile medicinal products. The new guidelines not only align processes with international best practices, but also encourage the adoption of technological innovations to ensure the safety and quality of pharmaceutical products. The harmonization of these standards, especially with the entry of ANVISA into the PIC/S, places Brazil at a high level of quality control, increasing the credibility and export potential of sterile products manufactured in the country.
The evolution of clean rooms, driven by these new guidelines, reinforces the importance of a controlled environment, free from contaminants, essential for the safety and effectiveness of medicines intended for human use. Companies dedicated to building clean rooms see changes as opportunities for innovation. They can continually improve equipment construction and installation processes. This ensures that facilities meet the highest quality and safety standards.
